Patents by Inventor Mark G. Bock

Mark G. Bock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIDAZINE DERIVATIVES AND RELATED USES
    Publication number: 20250115558
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: October 4, 2024
    Publication date: April 10, 2025
    Inventors: Mark G. BOCK, Samuel BROOKES, David HARRISON, M. Katharine HOLLOWAY
  • Selective inhibitors of NLRP3 inflammasome
    Patent number: 12247011
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: March 11, 2025
    Assignee: NodThera Limited
    Inventors: Mark G. Bock, David Harrison, Alan Paul Watt, Roderick Alan Porter, Nicolas Felix Pierre Boutard, Charles-Henry Robert Yves Fabritius, Grzegorz Witold Topolnicki, Oleksandr Levenets
  • BICYCLIC PHTHALAZIN-1(2H)-ONE DERIVATIVES AND RELATED USES
    Publication number: 20250066369
    Abstract: The present disclosure relates to compounds of Formula (III): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: January 6, 2023
    Publication date: February 27, 2025
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
    Publication number: 20240368129
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: May 7, 2024
    Publication date: November 7, 2024
    Inventors: David HARRISON, Alan Paul WATT, Mark G. BOCK
  • Sulfonylurea derivatives and uses thereof
    Patent number: 12054461
    Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 6, 2024
    Assignee: NodThera Limited
    Inventors: Mark G. Bock, David Harrison, Jane E. Scanlon
  • Sulphonyl urea derivatives as NLRP3 inflammasome modulators
    Patent number: 12012397
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: June 18, 2024
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Mark G. Bock
  • SULPHAMOYL UREA DERIVATIVES CONTAINING ALKYL-OXACYCLOALKYL MOIETY AND USES THEREOF
    Publication number: 20240043410
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: September 3, 2021
    Publication date: February 8, 2024
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
    Publication number: 20230145050
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: October 17, 2022
    Publication date: May 11, 2023
    Inventors: David HARRISON, Alan Paul WATT, Mark G. BOCK
  • SULFONYLUREA DERIVATIVES AND USES THEREOF
    Publication number: 20230083495
    Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: March 16, 2023
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • Sulphonyl urea derivatives as NLRP3 inflammasome modulators
    Patent number: 11518757
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 6, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Mark G. Bock
  • SULFONAMIDE DERIVATIVES AND USES THEREOF
    Publication number: 20220267300
    Abstract: The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: August 25, 2022
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • PPAR agonists
    Patent number: 11420934
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: August 23, 2022
    Assignees: The Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • SULFONYLUREA DERIVATIVES AND USES THEREOF
    Publication number: 20220227715
    Abstract: The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: June 11, 2020
    Publication date: July 21, 2022
    Inventors: Mark G. BOCK, David HARRISON, Jane E. SCANLON
  • CARBAMATE DERIVATIVES AND USES THEREOF
    Publication number: 20220098159
    Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: January 24, 2020
    Publication date: March 31, 2022
    Inventors: Mark G. BOCK, David HARRISON
  • SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME
    Publication number: 20210087147
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 25, 2021
    Inventors: Mark G. BOCK, David HARRISON, Alan Paul WATT, Roderick Alan PORTER, Nicolas Felix Pierre BOUTARD, Charles-Henry Robert Yves FABRITIUS, Grzegorz Witold TOPOLNICKI, Oleksandr LEVENETS
  • SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
    Publication number: 20210002261
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Application
    Filed: December 18, 2018
    Publication date: January 7, 2021
    Inventors: David HARRISON, Alan Paul WATT, Mark G. BOCK
  • PPAR AGONISTS
    Publication number: 20200190019
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: December 16, 2019
    Publication date: June 18, 2020
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • PPAR agonists
    Patent number: 10550071
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: February 4, 2020
    Assignees: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F. W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • PPAR AGONISTS
    Publication number: 20180170857
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: February 15, 2018
    Publication date: June 21, 2018
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Authur F. Kluge, Mike A. Patane
  • Glycoside derivatives and uses thereof
    Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang